KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Operating Margin (2016 - 2025)

Neogenomics (NEO) has disclosed Operating Margin for 16 consecutive years, with 7.05% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin rose 364.0% year-over-year to 7.05%, compared with a TTM value of 15.93% through Dec 2025, down 199.0%, and an annual FY2025 reading of 15.93%, down 199.0% over the prior year.
  • Operating Margin was 7.05% for Q4 2025 at Neogenomics, up from 14.38% in the prior quarter.
  • Across five years, Operating Margin topped out at 7.05% in Q4 2025 and bottomed at 44.4% in Q1 2022.
  • Average Operating Margin over 5 years is 20.87%, with a median of 18.7% recorded in 2021.
  • The sharpest move saw Operating Margin tumbled -3746bps in 2021, then soared 1884bps in 2023.
  • Year by year, Operating Margin stood at 33.06% in 2021, then skyrocketed by 42bps to 19.02% in 2022, then soared by 37bps to 11.94% in 2023, then grew by 10bps to 10.7% in 2024, then surged by 34bps to 7.05% in 2025.
  • Business Quant data shows Operating Margin for NEO at 7.05% in Q4 2025, 14.38% in Q3 2025, and 26.27% in Q2 2025.